• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国非酒精性脂肪性肝病的流行趋势演变:2010 年至 2022 年的发病率、患病率、进展及对医疗保健的影响。

Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022.

机构信息

Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.

出版信息

Korean J Intern Med. 2024 Nov;39(6):931-944. doi: 10.3904/kjim.2024.164. Epub 2024 Oct 24.

DOI:10.3904/kjim.2024.164
PMID:39444335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11569921/
Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD), now the most common chronic liver worldwide, has become a significant public health concern. This study aims to analyze the evolving epidemiology of NAFLD in South Korea.

METHODS

We utilized claim data from the Korean National Health Insurance Service from 2010 to 2022 to analyze NAFLD's incidence, prevalence, and progression.

RESULTS

From 2010 to 2022, the incidence and prevalence rates of NAFLD each increased from 1.87% to 4.47% and from 10.49% to 17.13%, respectively. The differences in prevalence rates between urban and rural areas were minimal in 2012 and 2022, yet both areas showed significant increases in the prevalence of NAFLD over the decade. The NAFLD group had a higher prevalence of comorbidities compared to the control group, and the most common comorbid condition was hypertension. Moreover, the ten-year incidence rates of malignancy, heart disease, and stroke in the NAFLD group were 13.42%, 15.72%, and 8.36%, respectively, which were significantly higher than those in the control group. The incidence rates of cirrhosis and hepatocellular carcinoma in NAFLD over 10 years were 2.22% and 0.77%, respectively. The total medical costs of NAFLD patients more than doubled over ten years and were all significantly higher than those of the control group.

CONCLUSION

A significant increase in NAFLD prevalence and its impact on healthcare utilization was observed in South Korea. With NAFLD leading to serious liver diseases and increased healthcare costs, integrated care strategies that include both medical treatment and lifestyle modifications are essential.

摘要

背景/目的:非酒精性脂肪性肝病(NAFLD)现已成为全球最常见的慢性肝病,已成为重大的公共卫生关注点。本研究旨在分析韩国 NAFLD 的流行趋势变化。

方法

我们利用韩国国家健康保险服务的索赔数据,分析 2010 年至 2022 年期间 NAFLD 的发病率、患病率和进展情况。

结果

从 2010 年至 2022 年,NAFLD 的发病率和患病率分别从 1.87%增至 4.47%和从 10.49%增至 17.13%。2012 年和 2022 年城乡地区的患病率差异较小,但十年来两个地区的 NAFLD 患病率均显著增加。与对照组相比,NAFLD 组的合并症患病率更高,最常见的合并症是高血压。此外,NAFLD 组恶性肿瘤、心脏病和中风的十年发病率分别为 13.42%、15.72%和 8.36%,明显高于对照组。NAFLD 患者在十年内肝硬化和肝细胞癌的发病率分别为 2.22%和 0.77%。NAFLD 患者的总医疗费用在十年内增加了一倍以上,均明显高于对照组。

结论

韩国 NAFLD 的患病率显著增加,对医疗保健利用的影响也越来越大。由于 NAFLD 可导致严重的肝脏疾病和增加医疗保健费用,因此需要采取综合护理策略,包括医疗治疗和生活方式改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/538afda5cea0/kjim-2024-164f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/76f111ae24cd/kjim-2024-164f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/552fa1ed0a6f/kjim-2024-164f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/c85d85a902b0/kjim-2024-164f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/d939503e8cfc/kjim-2024-164f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/40f27004b0b6/kjim-2024-164f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/9c5d43aea373/kjim-2024-164f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/ed67d99dcd23/kjim-2024-164f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/538afda5cea0/kjim-2024-164f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/76f111ae24cd/kjim-2024-164f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/552fa1ed0a6f/kjim-2024-164f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/c85d85a902b0/kjim-2024-164f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/d939503e8cfc/kjim-2024-164f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/40f27004b0b6/kjim-2024-164f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/9c5d43aea373/kjim-2024-164f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/ed67d99dcd23/kjim-2024-164f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0db5/11569921/538afda5cea0/kjim-2024-164f8.jpg

相似文献

1
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022.韩国非酒精性脂肪性肝病的流行趋势演变:2010 年至 2022 年的发病率、患病率、进展及对医疗保健的影响。
Korean J Intern Med. 2024 Nov;39(6):931-944. doi: 10.3904/kjim.2024.164. Epub 2024 Oct 24.
2
Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.意大利晚期肝病非酒精性脂肪性肝炎患者的医疗资源利用和费用。
Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):1014-1022. doi: 10.1016/j.numecd.2020.02.016. Epub 2020 Mar 5.
3
Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010.韩国人群中阻塞性肺疾病与非酒精性脂肪性肝病的关系:2007 - 2010年韩国国民健康与营养检查调查
Int J Chron Obstruct Pulmon Dis. 2018 Aug 28;13:2603-2611. doi: 10.2147/COPD.S166902. eCollection 2018.
4
NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.非酒精性脂肪性肝病患者中 NASH/肝纤维化、非肝脏合并症的流行率及代谢合并症与非酒精性脂肪性肝病发病率的相关性:来自韩国的经验。
Dig Dis. 2021;39(6):634-645. doi: 10.1159/000514953. Epub 2021 Feb 3.
5
Relationship Between Handgrip Strength and Nonalcoholic Fatty Liver Disease: Nationwide Surveys.握力与非酒精性脂肪性肝病的关系:全国性调查。
Metab Syndr Relat Disord. 2018 Nov;16(9):497-503. doi: 10.1089/met.2018.0077. Epub 2018 Aug 21.
6
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
7
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study.韩国年轻男性非酒精性脂肪性肝病的患病率趋势:一项基于韩国军人人群的横断面研究。
Clin Mol Hepatol. 2022 Apr;28(2):196-206. doi: 10.3350/cmh.2021.0371. Epub 2022 Jan 13.
8
Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.心血管危险因素和代谢综合征与非酒精性和酒精性脂肪性肝病的关系:一项回顾性分析。
BMC Endocr Disord. 2021 May 1;21(1):91. doi: 10.1186/s12902-021-00758-x.
9
Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study.非酒精性脂肪性肝病与胆道癌风险的相关性:一项韩国全国队列研究。
Eur J Cancer. 2021 Jun;150:73-82. doi: 10.1016/j.ejca.2021.03.024. Epub 2021 Apr 20.
10
Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的死亡率和疾病进展的模式和预测因素。
Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

引用本文的文献

1
Roadmap for HCC Surveillance and Management in the Asia Pacific.亚太地区肝癌监测与管理路线图
Cancers (Basel). 2025 Jun 10;17(12):1928. doi: 10.3390/cancers17121928.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening.韩国普通人群中代谢功能障碍相关脂肪性肝病:流行病学、危险因素及非侵入性筛查
Metabolites. 2025 Apr 30;15(5):299. doi: 10.3390/metabo15050299.
3
Statin use and liver-related prognosis among patients with MASLD.非酒精性脂肪性肝病(MASLD)患者使用他汀类药物与肝脏相关预后

本文引用的文献

1
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.肝细胞癌病因及流行病学的变化:亚洲及全球情况
J Liver Cancer. 2024 Mar;24(1):62-70. doi: 10.17998/jlc.2024.03.13. Epub 2024 Mar 25.
2
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences.五种心脏代谢危险因素在代谢功能障碍相关脂肪性肝病(MASLD)中的临床影响:对地区和种族差异的见解
Clin Mol Hepatol. 2024 Apr;30(2):168-170. doi: 10.3350/cmh.2024.0140. Epub 2024 Mar 5.
3
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
JHEP Rep. 2024 Dec 24;7(4):101313. doi: 10.1016/j.jhepr.2024.101313. eCollection 2025 Apr.
4
Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification.了解代谢功能障碍相关脂肪性肝病的流行病学对其管理至关重要:需要关注准确的诊断编码和分类。
Korean J Intern Med. 2024 Nov;39(6):869-871. doi: 10.3904/kjim.2024.351. Epub 2024 Nov 1.
全球非酒精性脂肪性肝病不良临床事件发生率:系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Apr;30(2):235-246. doi: 10.3350/cmh.2023.0485. Epub 2024 Jan 26.
4
Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma.肝脏疾病中的性别差异:临床前模型如何有助于剖析维持非酒精性脂肪性肝病和肝细胞癌的性别相关机制。
iScience. 2023 Oct 30;26(12):108363. doi: 10.1016/j.isci.2023.108363. eCollection 2023 Dec 15.
5
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma.肝细胞癌发病机制及危险因素中的性别差异
Biology (Basel). 2023 Jul 11;12(7):984. doi: 10.3390/biology12070984.
6
Non-alcoholic fatty liver disease-related hepatocellular carcinoma.非酒精性脂肪性肝病相关肝细胞癌
J Liver Cancer. 2023 Mar;23(1):127-142. doi: 10.17998/jlc.2022.12.30. Epub 2023 Feb 9.
7
Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study.韩国肝细胞癌国家癌症监测项目中超声检查的现状:一项大规模多中心研究
J Liver Cancer. 2023 Mar;23(1):189-201. doi: 10.17998/jlc.2023.03.11. Epub 2023 Mar 24.
8
Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology.韩国肝细胞癌患者病因相关的临床特征及预后
J Liver Cancer. 2022 Sep;22(2):158-166. doi: 10.17998/jlc.2022.09.18. Epub 2022 Sep 27.
9
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
10
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学:病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.